BackImmatics N.V - Warrants (01/07/2025) Overview

Immatics N.V - Warrants (01/07/2025) EBIT

Immatics N.V - Warrants (01/07/2025)'s EBIT is $-230M, below the Healthcare sector average of $22B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$68.32M
3.92% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$229.07M
225.75% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Immatics N.V - Warrants (01/07/2025) (IMTXW) FAQ

The latest EBIT for IMTXW is $-230M as of June 2026. That compares with $-70M in the prior-year period — down 225.8% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Immatics N.V - Warrants (01/07/2025)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, IMTXW's EBIT moved from $-70M to $-230M — a 225.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Immatics N.V - Warrants (01/07/2025)'s operating scale or balance-sheet position.

Against Healthcare companies, IMTXW currently prints $-230M for EBIT, while the sector average sits near $22B. That is roughly 101.0% below the sector mean. Large gaps often invite a closer look at Immatics N.V - Warrants (01/07/2025)'s growth, margins, and balance sheet.

A EBIT figure of $-230M for IMTXW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting IMTXW's EBIT ($-230M), review year-over-year change from $-70M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.